History of HAS Healthcare Advanced Synthesis
We are known for our strong heritage and track record. We have been delivering clinical and commercial compounds successfully to our clients since 1984.
Since our foundation, we have delivered hundreds of projects. Our track record of experience and know-how makes us well positioned to meet the needs of our pharmaceutical and biotech clients.
HAS Healthcare Advanced Synthesis was first established by the Braglia family as part of the Helsinn Group. Our manufacturing site is located in Biasca, Switzerland.
Since our foundation, we have delivered hundreds of projects. Our track record of experience and know-how makes us well positioned to meet the needs of our pharmaceutical and biotech clients.
HAS Healthcare Advanced Synthesis was first established by the Braglia family as part of the Helsinn Group. Our manufacturing site is located in Biasca, Switzerland.
Milestones
Helsinn Chemicals SA, the first manufacturing facility of the Group, opens in Switzerland in Biasca and receives its initial audit
First audit by U.S. FDA (U.S. Food and Drug Administration)
Helsinn Advanced Synthesis SA, the second Swiss production facility, opened in Biasca, dedicated to highly potent pharmaceutical active ingredients
HAS receives ISO 14001 certification
HAS Audit by the Korean FDA HAS receives OHSAS18001 certification
HAS Audit by Japan's PMDA2010
Merger Between Helsinn Chemicals SA and Helsinn Advanced Synthesis SA. The manufacturing facility is now named Helsinn Advanced Synthesis SA
Opening a new chemical plant to produce Anticancer products at HAS Completion of the construction of the Anticancer area: an investment supported in part by the Cantonal Authorities through the Office for Economic Development
Helsinn Advanced Synthesis SA is the first private company in Ticino, Switzerland, to prepare a Sustainability Report in accordance with the Global Reporting Initiative (GRI)
HAS obtained the renewal of its OHSAS 18001 certification
Helsinn Advanced Synthesis unveils its new anticancer ingredients plant and drastically reduces emission by shifting from heating oil to renewable energy by latching on the district heating plant system of Nuova Energia Ticino (NET)
The Swiss Agency for Therapeutic Products (Swissmedic) inspected the new facility in June 2020 and approved manufacturing to start Opening of new Anticancer production unit in Biasca for the development, analysis, and manufacturing of anticancer APIs
In 2021, with a CHF 10 million investment, we began constructing a new state-of-the-art Quality Control (QC) laboratory center with the highest standards and cutting-edge technologies. The construction work commenced in September 2021 and is scheduled to conclude by the end of 2023, with the new laboratories becoming operational in the early part of 2024. This expansion will enable us to accommodate the growing needs of our company as our current laboratory space is no longer sufficient.
HAS Healthcare Advanced Synthesis achieves Carbon Neutrality.
In January 2022, Helsinn Advanced Synthesis formalizes its launch as independent company, splitting its activities from Helsinn Group. Along the spin-off process, the company name is changed to HAS Healthcare Advanced Synthesis SA. Future Goals: We are currently evaluating the implementation of a new production facility consisting of three distinct production units. With an estimated total investment of approximately 70-80 million Swiss francs, this project will enhance our existing capabilities.
HAS Healthcare Advanced Synthesis SA (Biasca, Switzerland) celebrates 40 years of Excellence in Pharmaceutical Development and Manufacturing
This year also marks the completion of the New Cutting-Edge Quality & Control laboratory Center.
